Metamizol Chalim (Metamizole Magnesium)

Metamizole magnesium works by inhibiting cyclooxygenase enzymes, which lowers prostaglandin production, and by modulating central pain pathways in the spinal cord and brain. This combined effect diminishes the perception of pain and helps lower elevated body temperature.

The appropriate dose of Metamizol Chalim is determined by the prescribing healthcare professional based on the patient’s condition, age, weight, and response to therapy. Dosage instructions are provided on the prescription label and should be followed exactly as directed.

Safety of metamizole magnesium in pregnancy or lactation has not been fully established. It should only be used if the potential benefit justifies the possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To order Metamizol Chalim, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Metamizole Chalim belongs to the pyrazolone class, offering strong analgesic and antipyretic effects with less anti‑inflammatory activity than traditional NSAIDs. Compared with drugs like ibuprofen or paracetamol, it may provide more rapid pain relief but carries a higher risk of rare blood‑related side effects, requiring careful monitoring.

Metamizol Chalim should be stored at ambient temperature, below 25 °C, in its original packaging. Protect the tablets from moisture, direct sunlight, and excessive heat to maintain potency and stability throughout its shelf life.

Metamizol Chalim is administered orally, typically as a tablet that is swallowed with water. The exact administration schedule, including timing relative to meals, is determined by the prescribing clinician and should be followed as indicated on the prescription label.

The most serious risks include agranulocytosis, a potentially life‑threatening drop in white‑blood‑cell count, and severe skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored for signs of infection, unusual bruising, or skin changes, and seek immediate medical attention if these occur.

Metamizol Chalim should be avoided in individuals with a known hypersensitivity to metamizole or other pyrazolones, those with a history of agranulocytosis, severe liver or kidney impairment, and patients for whom safer alternatives are available. A healthcare professional should evaluate suitability before prescribing.